Albert David Ltd is Rated Sell

2 hours ago
share
Share Via
Albert David Ltd is rated 'Sell' by MarketsMojo, with this rating last updated on 11 February 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 01 April 2026, providing investors with an up-to-date view of the company's performance and outlook.
Albert David Ltd is Rated Sell

Current Rating and Its Significance

MarketsMOJO currently assigns Albert David Ltd a 'Sell' rating, indicating a cautious stance towards the stock. This rating suggests that investors should consider reducing exposure or avoiding new purchases, given the company's present fundamentals and market conditions. The 'Sell' grade reflects a combination of factors including quality, valuation, financial trends, and technical indicators, which collectively point to challenges ahead for the stock.

Quality Assessment

As of 01 April 2026, Albert David Ltd's quality grade is assessed as average. This implies that while the company maintains a baseline operational standard, it lacks the robust growth and profitability metrics that typically characterise higher-quality stocks in the Pharmaceuticals & Biotechnology sector. Notably, the company has experienced poor long-term growth, with operating profit declining at an annualised rate of -239.68% over the past five years. Such a steep contraction in profitability raises concerns about the sustainability of its business model and competitive positioning.

Valuation Considerations

The valuation grade for Albert David Ltd is classified as risky. The stock is currently trading at valuations that are less favourable compared to its historical averages, reflecting investor apprehension. Negative EBITDA further compounds this risk profile, signalling that the company is not generating sufficient earnings before interest, taxes, depreciation, and amortisation to cover its operational costs. This financial strain is mirrored in the stock’s performance, which has delivered a negative return of -26.82% over the past year as of 01 April 2026. Such valuation concerns suggest limited upside potential and heightened downside risk for investors.

Financial Trend Analysis

Despite the challenges, the financial grade is marked as positive, indicating some favourable aspects in the company’s recent financial trajectory. However, this positive trend is overshadowed by significant profit erosion, with profits falling by -76.2% over the last year. The disparity between the positive financial grade and deteriorating profitability highlights a complex financial picture, where certain metrics may be improving but overall earnings performance remains weak. Investors should carefully weigh these mixed signals when considering the stock’s prospects.

Technical Outlook

The technical grade for Albert David Ltd is bearish, reflecting negative momentum in the stock’s price action. Recent returns reinforce this view, with the stock declining by -17.33% year-to-date and showing losses across multiple time frames: -5.88% over one week, -13.72% over one month, and -21.36% over six months. This sustained downward trend suggests that market sentiment remains subdued, and technical indicators do not currently support a near-term recovery.

Performance Relative to Benchmarks

Albert David Ltd has underperformed key market indices such as the BSE500 over the last three years, one year, and three months. This underperformance, combined with the stock’s negative returns and challenging fundamentals, underscores the difficulties faced by the company in delivering shareholder value. Investors should consider these comparative metrics when evaluating the stock’s attractiveness relative to other opportunities in the Pharmaceuticals & Biotechnology sector.

Momentum just kicked in! This Small Cap from the Auto - Trucks sector entered our list with explosive short-term signals. Catch the wave while it's still building!

  • - Fresh momentum detected
  • - Explosive short-term signals
  • - Early wave positioning

Catch the Wave Now →

Implications for Investors

For investors, the 'Sell' rating on Albert David Ltd signals caution. The average quality, risky valuation, mixed financial trends, and bearish technical outlook collectively suggest that the stock may face continued headwinds. Those currently holding the stock might consider reassessing their positions in light of the negative returns and profit declines. Prospective investors should weigh the risks carefully, recognising that the current market environment and company fundamentals do not favour a bullish stance.

Sector Context and Market Capitalisation

Albert David Ltd operates within the Pharmaceuticals & Biotechnology sector, a space often characterised by innovation and growth potential. However, the company’s microcap status and recent financial struggles place it at a disadvantage compared to larger, more stable peers. The sector’s overall performance and investor sentiment towards pharmaceutical stocks should be monitored closely, as these factors can influence Albert David Ltd’s future prospects.

Summary of Key Metrics as of 01 April 2026

The latest data shows the stock’s one-day gain at +4.22%, a modest uptick amid broader declines. However, longer-term returns remain negative: -5.88% over one week, -13.72% over one month, -17.33% year-to-date, and -26.82% over one year. Operating profit has contracted sharply over five years, and profits have fallen by over three-quarters in the past year. These figures highlight the challenges facing Albert David Ltd and underpin the current 'Sell' rating.

Conclusion

In conclusion, Albert David Ltd’s 'Sell' rating by MarketsMOJO reflects a comprehensive evaluation of its current financial health, valuation risks, and market performance as of 01 April 2026. Investors should interpret this rating as a signal to exercise caution, given the company’s average quality, risky valuation, mixed financial trends, and bearish technical indicators. While the stock may present opportunities for speculative traders, a conservative approach is advisable for long-term investors seeking stability and growth within the Pharmaceuticals & Biotechnology sector.

{{stockdata.stock.stock_name.value}} Live

{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)

{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)


Our weekly and monthly stock recommendations are here
Loading...
{{!sm.blur ? sm.comp_name : ''}}
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Entry Price
Target Price
{{sm.target_price }} ({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News
Albert David Ltd is Rated Sell
Mar 21 2026 10:10 AM IST
share
Share Via
Albert David Ltd Stock Falls to 52-Week Low of Rs.601
Mar 16 2026 11:28 AM IST
share
Share Via
Albert David Ltd is Rated Sell
Mar 10 2026 10:10 AM IST
share
Share Via
Albert David Ltd is Rated Sell
Feb 27 2026 10:10 AM IST
share
Share Via
Albert David Ltd is Rated Sell
Feb 16 2026 10:10 AM IST
share
Share Via